

ATUM accelerates entry of bioengineering solutions into Chinese pharmaceutical market

April 21, 2022 | News

ATUM's Leap-In Transposase platform enables rapid, robust, and efficient manufacturing of high-quality protein pharmaceuticals



US-based ATUM has announced a distribution partnership with Trio Biotech to market and promote ATUM's unique Leap-In Transposase platform in China. ATUM's Leap-In platform offers bioengineering solutions for efficient cell line development, genome engineering, and robust production of pharmaceutical biologics.

TrioBio is well established in China as the premier distributor of life science tools and instruments to facilitate cell imaging, clonality validation, and automated cell plating and tracking.

With locations in Shanghai and Beijing and deep expertise in cell line development, TrioBio is poised to bring the Leap-In Transposase platform to Chinese pharmaceutical companies seeking support in their manufacturing of protein pharmaceuticals, viral drug delivery vehicles, and cell-based drugs.